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Background: In patients with acute coronary syndromes, an increase in hemorrhagic complications has been
observed, and bleeding is now the most frequent noncardiac complication in these patients. Clinical trials
and registries have used different scales to classify the severity of bleeding; so far, none of them has been
developed for ST-segment elevation myocardial infarction (STEMI) patients in the era of primary percutaneous
coronary intervention.
Methods: We analyzed data from our Intensive Cardiac Care Florence STEMI Registry, comprising 991 STEMI
patients consecutively admitted to our intensive cardiac care unit after mechanical revascularization, to assess
the clinical impact of both Thrombolysis In Myocardial Infarction (TIMI) and Acute Catheterization and Urgent
Intervention Triage Strategy (ACUITY) classifications in identifying patients with major bleeding at higher risk
for in-hospital mortality.
Results: Major bleeding events occurred in 8.9% of patients (88/991) in the TIMI classification and in 17.2%
of patients (170/991) in the ACUITY classification. Among patients with major bleeding classified according to
ACUITY, 82 patients did not meet the TIMI criteria for major bleeding. These patients represent the so-called
gray zone, where no transfusion was performed and only 1 patient died.
Conclusions: In STEMI patients who undergo primary percutaneous coronary intervention and receive dual
antiplatelet therapy, TIMI is more capable than ACUITY in identifying patients with major bleeding at higher
risk for early mortality. The presence of renal failure represents an independent predictor for major bleeding.
Introduction
Percutaneous coronary intervention (PCI), along with
the widespread adoption of newer antithrombotic and
antiplatelet regimens, has resulted in significant improve-
ment in ischemic outcomes of patients with acute coronary
syndromes (ACS) and ST-segment elevation myocardial
infarction (STEMI).1,2 However, an increase in hemor-
rhagic complications has been observed, and bleeding is
now the most frequent noncardiac complication of patients
with ACS.1–4 Major bleeding events are known to negatively
influence prognosis, prolong the hospital stay, and increase
costs.1,3
Clinical trials and registries of patients with ACS have
used different scales to classify the severity of bleeding;
so far, none has been developed for STEMI patients in
the era of primary PCI. In the Harmonizing Outcomes
with Revascularization and Stents in Acute Myocardial
Infarction trial (HORIZONS-AMI),5 major bleeding events
were classified according to the criteria of the Acute
The authors have no funding, financial relationships, or conflicts
of interest to disclose.
Catheterization and Urgent Intervention Triage Strategy
(ACUITY) trial,6 which enrolled patients with moderate-
and high-risk ACS. Differences in various classifications can
account for differences in the estimated prevalence of major
bleeding.1,3,5–8 The Thrombolysis In Myocardial Infarction
(TIMI) classification7 for major bleeding is one of the most
commonly used, whereas the ACUITY criteria6 have been
developed in ACS patients subjected to invasive treatment
and antiplatelet and antithrombotic therapies.
We analyzed data from our Intensive Cardiac Care
Florence STEMI Registry, comprising 991 STEMI patients
consecutively admitted to our intensive cardiac care unit
(ICCU) after PCI, to assess the clinical impact of both
TIMI and ACUITY classifications in identifying patients
with major bleeding at higher risk for in-hospital mortality.
Methods
The clinical, angiographic, and in-hospital outcomes of
991 consecutive patients with STEMI (within 12 hours
from symptom onset) who were admitted at our ICCU
from January 1, 2004 to December 31, 2008 were stored
prospectively in a dedicated database (Intensive Cardiac
Care Florence STEMI Registry). All STEMI patients
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underwent primary PCI and then were admitted to the
ICCU.9–11
The diagnosis of STEMI was based on the American Col-
lege of Cardiology/American Heart Association criteria.12
Coronary angiography and angioplasty were performed
using standard techniques by percutaneous femoral
approach (using 6-Fr sheaths). Before PCI, a 70-IU/kg intra-
venous bolus of unfractionated heparin was administered
(maximum 5000 IU), followed by additional weight-adjusted
doses, in order to maintain an activated clotting time ≥250
seconds throughout the procedure. All patients were given
500 mg of aspirin and 300–600 mg of clopidogrel. Glycopro-
tein IIb/IIIa inhibitors (GPI) were administered according
to the operator’s judgment.
A successful PCI was defined as an infarct-artery stenosis
<20% associated with TIMI grade 3 flow. Failure PCI was
defined as resulting in TIMI grade 0–2 flow, regardless of
the residual stenosis.13
Upon ICCU admission, blood samples were obtained for
cell count, cardiac biomarkers, serum glucose and crea-
tinine levels, high-sensitivity C-reactive protein (hs-CRP),
erythrocyte sedimentation rate (ESR), and platelet counts.
For the present analysis, the following hemoglobin (Hb)
values were used: Hb on ICCU admission and nadir Hb
(the lowest Hb value during the ICCU stay). Estimated
glomerular filtration rate (eGFR) was calculated according
to the Levey modified Modification of Diet in Renal Disease
(MDRD) formula.14 Transthoracic 2-dimensional echocar-
diography was performed on admission in order to measure
left ventricular ejection fraction (LVEF).
Definition of Major Bleeding
TIMI5: Intracranial hemorrhage, a ≥5 g/dL decrease in Hb
concentration, or a ≥15% absolute decrease in hematocrit.
ACUITY6: Intracranial or intraocular bleeding; access-
site hemorrhage requiring intervention, ≥5-cm-diameter
hematoma, clinically overt blood loss with hemoglobin
decrease ≥3 g/dL, any hemoglobin decrease ≥4 g/dL, or
blood-product transfusion.
Statistical Analysis
Statistical analysis was performed using SPSS 13.0 for Win-
dows (SPSS Inc., Chicago, IL). Data are reported as frequen-
cies and percentages ormedians (25th and 75th percentiles)
and analyzed by means of χ2 test (or Fisher exact text
and Mann-Whitney U test, respectively; in χ2 calculations,
when appropriate, post hoc tests were performed taking
into account standardized residuals). A multivariate back-
ward stepwise logistic regression analysis was performed to
determine the independent predictors of major bleeding.
Variables that, in the univariate analysis, resulted in a
significant difference between subgroups at a probability
level <0.01 were entered into the multivariable model;
namely age, weight, gender, admission systolic blood pres-
sure (SBP), admission heart rate (HR), Killip class, MI
location, LVEF, PCI failure, eGFR, admission Hb, intra-
aortic balloon pump (IABP), ultrafiltration, and mechan-
ical ventilation. A 2-tailed P value <0.05 was considered
significant.
Results
Table 1 shows the baseline characteristics of the 991
STEMI patients included in the study, all treated with
primary PCI. The overall population was classified accord-
ing to TIMI major bleeding (left side of table) and ACUITY
(right side of table). Major bleeding events occurred in 8.9%
of patients (88/991) in the TIMI classification and in 17.2%
of patients (170/991) in the ACUITY classification.
TIMI Major Bleeding Classification
The STEMI patients who experienced major bleeding were
older (P < 0.001), more frequently female (P = 0.007),
leaner (P = 0.008), and had chronic renal failure (P <
0.001) (Table 1). On admission (Table 2), STEMI patients
who experienced major bleeding showed higher HR (P <
0.001), lower SBP (P = 0.003), and a lower percentage of
ST decrease (P = 0.013). In these patients, anterior MI
was more frequent (P = 0.002), as well as Killip class IV
(P < 0.001), whereas LVEF was lower (P < 0.001). The
use of a bare-metal stent was higher in patients who
experienced major bleeding (Table 2). The rate of bleeding
was higher (P = 0.004) among patients who had PCI
failure. The use of GPIs was higher in patients who
had no bleeding events (P = 0.039). Major bleeding was
associated (Table 3) with higher values of TnI (P < 0.001),
glucose (P < 0.001), positive hs-CRP (P < 0.001), and
ESR (P = 0.004), and with lower values of eGFR
(P < 0.001), admission Hb (P < 0.001), and, obviously,
nadir Hb (P < 0.001). No difference was observed in
platelet count on admission. The use of devices was
more frequent in patients who experienced major bleeding
events (P < 0.001) (Table 4). All blood transfusions were
performed in major bleeding events (67/88, 76%; P <
0.001). Intra-ICCU mortality was higher in patients who
had major bleeding (20% vs 3%; P < 0.001).
ACUITY Classification
Major bleeding was observed in older and leaner patients
(P = 0.004 and 0.001, respectively), in females (P =
0.016), and in patientswith chronic renal failure (P = 0.010)
(Table 1). Patients who experienced major bleeding events
showed, on ICCU admission, higher HR (P < 0.001) and
lower percentage of ST decrease (P = 0.023), together
with a higher Killip class (P < 0.001), a higher incidence
of anterior MI (P < 0.001), and a lower LVEF (P <
0.001). In these patients, PCI failure was more frequent
(P = 0.012), and they showed (Table 3) higher values of
TnI (P < 0.001), glucose (P < 0.001), positive hs-CRP
(P < 0.001), and ESR (P = 0.015), and lower values of
eGFR (P < 0.001) as well as nadir Hb (P < 0.001). No
difference was observed in admission Hb and in platelet
count. Major bleeding was associated with a more frequent
use of devices (P < 0.001) (Table 4).
All blood transfusions were performed in major bleeding
events (67/170, 39.4%; P < 0.001). Intra-ICCU mortality
was higher in patients who had major bleeding (11.2% vs
3.2%, P < 0.001).
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Table 1. Baseline Characteristics of the 991 STEMI Study Patients
TIMI-I ACUITY
No Major Bleeding,
n= 903 (91.9%)
Major Bleeding,
n= 88 (8.9%) P Value
No Major Bleeding,
n=821 (82.8%)
Major Bleeding,
n= 170 (17.2%) P Value
Demographics
Median age, y (25th, 75th percentiles) 67 (58, 76) 75 (64, 80) <0.001 67 (58, 76) 72 (60, 78) 0.004
Female sex 24.6 38.6 0.007 24.2 33.5 0.016
Median weight, kg (25th, 75th percentiles) 75 (65, 83) 70 (62, 80) 0.008 75 (65, 83) 70 (63, 80) 0.001
Medical history
DM 24.7 31.8 0.158 25.1 26.8 0.628
Hypertension 52.4 51.1 0.824 51.0 58.3 0.090
Dyslipidemia 36.7 29.5 0.202 36.0 36.3 0.930
Smoking 63.3 48.9 0.011 63.0 56.8 0.139
Chronic renal failure 3.4 12.5 <0.001 3.4 8.2 0.010
COPD 8.0 11.4 0.307 8.2 8.8 0.761
Prior MI 14.3 20.5 0.156 14.4 17.1 0.406
Prior stroke 3.5 8.0 0.075 3.5 5.9 0.190
Prior PCI 13.5 19.3 0.147 13.8 15.3 0.628
Prior CABG 2.2 2.3 1 2.0 3.5 0.247
Abbreviations: ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; CABG, coronary artery bypass graft; COPD, chronic obstructive
pulmonary disease; DM, diabetes mellitus; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction;
TIMI-I, Thrombolysis In Myocardial Infarction-I.
Numbers are percentages unless otherwise noted.
Gray Zone
Among patients with major bleeding events classified
according to ACUITY, 82 patients did not meet the TIMI
criteria for major bleeding. These patients represent a
subgroup that we named the gray zone (Table 5). The
patients included in the gray zone showed major bleeding
according to the ACUITY criteria, but no transfusion was
performed and only 1 patient died.
Major Bleeding Sites
Clinical bleeding was identified in 66 (75%) of the patients
with major bleeding according to TIMI criteria. The most
frequent bleeding events were femoral groin hematoma
(44.3%), gastrointestinal hemorrhage (10.2%) and retroperi-
toneal bleeding (4.5%), urinary tract hemorrhage (2.3%),
cerebral hemorrhage (1.1%), cardiac tamponade (4.5%),
respiratory tract hemorrhage (4.5%), and disseminated
intravascular coagulopathy (3.4%).
Clinical bleeding was identified in 100 (59%) of the
patients with major bleeding according to ACUITY
criteria. The most frequent bleeding events were femoral
groin hematoma (40.6%), gastrointestinal hemorrhage
(6.5%) and retroperitoneal bleeding (2.4%), urinary tract
hemorrhage (1.8%), cerebral hemorrhage (0.6%), cardiac
tamponade (2.9%), respiratory tract hemorrhage (2.4%), and
disseminated intravascular coagulopathy (1.8%).
Logistic Regression Analysis
At backward stepwise logistic regression analysis, per-
formed until all covariates resulted statistically significant,
the following variables were independent predictors of
intra-ICCU major bleeding according to TIMI criteria:
IABP (odds ratio [OR]: 2.96, 95% confidence interval [CI]:
1.39–6.34, P = 0.005), mechanical ventilation (OR: 5.08,
95% CI: 2.19–11.78, P < 0.001), eGFR (OR: 0.97, 95% CI:
0.95–0.98, P < 0.001), admission Hb (OR: 0.82, 95% CI:
0.69–0.97, P = 0.022), and Hosmer-Lemeshow test (4.80,
P = 0.779).
At the same statistical analysis, the following variables
resulted as independent predictors of intra-ICCU major
bleeding according to ACUITY criteria: IABP (OR: 3.59,
95% CI: 2.14–6.02, P < 0.001), weight (OR: 0.98, 95% CI:
0.96–0.99, P = 0.011), eGFR (OR: 0.98, 95% CI: 0.97–0.99,
P < 0.001), ultrafiltration (OR: 5.95, 95% CI: 1.91–18.5,
P = 0.002), andHosmer-Lemeshow test (9.98, P = 0.266).
Discussion
The main finding of the present investigation is that, in
991 consecutive STEMI patients treated with primary PCI,
TIMI classification is able to identify patients with major
bleeding at higher risk for intra-ICCU mortality, whereas
the ACUITY classification includes also a subgroup of
patients (the gray zone) showing bleeding events not able
to affect their outcomes in the short term.
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Table 2. Clinical Characteristics of the 991 STEMI Study Patients
TIMI-I ACUITY
Presenting Signs
No Major Bleeding,
n= 903 (91.9%)
Major Bleeding,
n= 88 (8.9%) P Value
No Major Bleeding,
n=821 (82.8%)
Major Bleeding,
n= 170 (17.2%) P Value
Median HR, bpm (25th, 75th percentiles) 77 (66, 87) 80 (71, 100) <0.001 77 (65, 86) 80 (70, 96) <0.001
Median SBP, mm Hg (25th, 75th percentiles) 130 (115, 145) 120 (98, 140) 0.003 130 (115, 145) 130 (104, 150) 0.106
ST decrease >50% 64.6 47.3 0.013 65.1 53.2 0.023
Killip class <0.001 <0.001
I 82.6 48.3a 83.0 62.7a
II 8.4 14.9 8.4 11.8
III 2.7 4.6 2.6 4.1
IV 6.3 32.2a 6.0 21.3a
AMI location 0.002 <0.001
Inferior 39.7 23.3a 40.8 26.2a
Lateral 8.1 4.7 8.2 6.0
Anterior 52.2 72.1a 51.0 67.9a
Median LVEF, % (25th, 75th percentiles) 45 (38, 50) 35 (30, 45) <0.001 45 (38, 50) 40 (30, 45) <0.001
CAD 0.500 0.122
No disease 0.2 0.0 0.2 0.0
1-vessel 39.8 32.2 40.8 31.4
2-vessel 34.0 40.2 33.7 38.5
3-vessel 26.0 27.6 25.3 30.2
Left main 7.3 13.1 0.083 6.9 12.1 0.036
CABG 1.6 2.3 0.609 1.5 2.4 0.499
IRA <0.001 <0.001
RCA 33.7 17.6a 34.7 20.7a
CX 12.2 14.0 12.4 12.1
DA 52.4 61.3 51.3 62.3
Left main 0.7 5.9a 0.7 3.1a
CABG 1.0 1.2 0.9 1.8
Stent implantation 89.4 85.2 0.313 89.6 86.2 0.284
BMS 46.9 61.4 47.1 53.5
DES 42.8 28.4 0.024 42.4 37.6 0.293
POBA 10.3 10.2 10.5 8.9
Clin. Cardiol. 34, 2, 90–96 (2011) 93
S. Valente et al: Comparison between classifications of STEMI patients
Published online in Wiley Online Library (wileyonlinelibrary.com)
DOI:10.1002/clc.20842 2011 Wiley Periodicals, Inc.
Table 2. Continued
TIMI-I ACUITY
Presenting Signs
No Major Bleeding,
n= 903 (91.9%)
Major Bleeding,
n=88 (8.9%) P Value
No Major Bleeding,
n=821 (82.8%)
Major Bleeding,
n= 170 (17.2%) P Value
TIMI flow post-PCI 0.002 0.041
III 94.6 86.0 94.8 89.3
II 3.4 10.5a 3.5 6.5
I 0.9 0.0 0.7 1.2
0 1.1 3.5 1.0 3.0
PCI failure 5.4 13.8 0.004 5.2 10.7 0.012
GPI 70.2 59.1 0.039 69.4 68.2 0.784
Abbreviations: ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; AMI, acute myocardial infarction; BMS, bare-metal stent; CABG,
coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CX, circumflex coronary artery; DA, descending
anterior coronary artery; DES, drug-eluting stent; DM, diabetes mellitus; GPI, glycoprotein IIb/IIIa inhibitor; HR, heart rate; IRA, infarct-related artery;
LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; POBA, plain old balloon angioplasty; RCA, right
coronary artery; SBP, systolic arterial blood pressure; ST, ST segment; STEMI, ST-elevation myocardial infarction; TIMI-I, Thrombolysis In Myocardial
Infarction-I. Numbers shown are percentages unless otherwise noted. aP < 0.05.
Table 3. Biochemical Data on the 991 STEMI Study Patients
TIMI-I ACUITY
No Major Bleeding,
n= 903 (91.9%)
Major Bleeding,
n=88 (8.9%) P Value
No Major Bleeding,
n=821 (82.8%)
Major Bleeding,
n= 170 (17.2%) P Value
TnI, ng/mL (25th, 75th
percentiles)
84.1 (37.8, 168.2) 129.0 (55.4, 370.0) <0.001 82.0 (37.3, 164.0) 123.3 (50.1, 255.3) <0.001
Glycemia, g/L (25th,
75th percentiles)
1.30 (1.11, 1.62) 1.65 (2.32, 2.40) <0.001 1.29 (1.10, 1.62) 1.52 (1.24, 2.02) <0.001
eGFR mL/min/1.73 m2
(25th, 75th
percentiles)
81.2 (67.0, 98.2) 57.0 (37.3, 74.5) <0.001 81.3 (68.1, 98.1) 68.8 (45.7, 83.7) <0.001
ESR, mm/h (25th, 75th
percentiles)
25 (14, 42) 32 (18, 69) 0.004 25 (14, 42) 30 (18, 51) 0.015
Positive hs-CRP, % 53.8 76.1 <0.001 52.6 70.8 <0.001
Admission Hb, g/dL
(25th, 75th
percentiles)
13.8 (12.7, 14.7) 12.2 (10.2, 14.1) <0.001 13.7 (12.6, 14.6) 13.4 (11.6, 14.8) 0.355
Nadir Hb, g/dL (25th,
75th percentiles)
12.0 (10.7, 13.0) 8.2 (7.6, 9.3) <0.001 12.1 (11.0, 13.0) 9.3 (8.1, 10.5) <0.001
Platelet count,
∗1000/ mL (25th, 75th
percentiles)
210 (176, 253) 233 (181, 294) 0.204 210 (175, 253) 223 (180, 268) 0.184
Abbreviations: ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; eGFR, estimated glomerular filtration rate; ESR, erythrocyte
sedimentation rate; Hb, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; STEMI, ST-elevation myocardial infarction; TnI, troponin I; TIMI-I,
Thrombolysis In Myocardial Infarction-I.
Numbers shown are percentages unless otherwise noted.
Bleeding rates are known to depend mainly on the
clinical setting15–17 and on the definition of bleeding
events.1,3 Taking into account that our series comprises
a homogeneous population of STEMI patients, all treated
with primary PCI by femoral approach, we confirm that
classification type does influence the prevalence of bleeding
events (8.9% according to TIMI I; 17.8% according to
ACUITY).
On a clinical ground, the role of classifications is to provide
tools to identify patients at higher risk. Our findings strongly
suggest that, in STEMI patients who undergo primary PCI
and receive dual antiplatelet therapy, TIMI is more capable
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Table 4. Device Use in the 991 STEMI Study Patients
TIMI-I ACUITY
No Major Bleeding,
n= 903 (91.9%)
Major Bleeding,
n=88 (8.9%) P Value
No Major Bleeding,
n=821 (82.8%)
Major Bleeding,
n= 170 (17.2%) P Value
IABP 24.1 60 <0.001 22.1 52.4 <0.001
CVVHDF 2.1 26.8 <0.001 1.6 17.4 <0.001
Mechanical ventilation 5.4 35.3 <0.001 5.2 21.7 <0.001
NIV 3.8 30.8 <0.001 3.2 20.3 <0.001
Blood transfusion 0.0 76.1 <0.001 0.0 39.4 <0.001
In-ICCU deaths 3.0 20.5 <0.001 3.2 11.2 <0.001
Abbreviations: ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; CVVHDF, continuous venovenous hemodiafiltration; IABP, intra-
aortic balloon pump; ICCU, intensive coronary care unit; NIV, noninvasive ventilation; STEMI, ST-elevation myocardial infarction; TIMI-I, Thrombolysis In
Myocardial Infarction-I.
Numbers shown are percentages.
Table 5. Comparison Between the Gray Zone and TIMI Major Bleeding
Gray Zone TIMI Major Bleeding P Value
Number 82 88
Mortality 1 (1.2%) 18 (20.4%) <0.001
Blood transfusion 0 (0%) 67 (76.1%) <0.001
PCI failure 6 (7.3%) 12 (13.6%) NS
IABP 36 (43.9%) 51 (58.0%) <0.001
NIV 7 (8.5%) 24 (27.2%) <0.001
Mechanical ventilation 6 (7.3%) 30 (34.1%) <0.001
CVVHDF 6 (7.3%) 22 (25.0%) <0.001
Abbreviations: CVVHDF, continuous venovenous hemodiafiltration;
IABP, intra-aortic balloon pump; NIV, noninvasive ventilation; NS, not
significant;PCI, percutaneouscoronary intervention;TIMI, Thrombolysis
In Myocardial Infarction.
than ACUITY in identifying patients with major bleeding
events at higher risk for mortality.
Moreover, according to our data, the entity of bleeding,
and not only ‘‘bleeding’’ itself, affects prognosis, because
patients in the gray zone, though classified as ‘‘major
bleeding,’’ did not show an increased rate of mortality and
were not transfused.
According to both classifications (TIMI and ACUITY)
and in agreement with the investigations by Nikolsky et al18
and by Mehran et al,19 the presence of chronic renal failure
was an independent predictor of in-ICCUmajor bleeding. As
recently reported,20 GFRshould be systematicallymeasured
for every single patient and monitored during treatment to
guide the choice of drug and dose.
The severity of critical illness, as inferred by the presence
of devices (ultrafiltration, IABP, mechanical ventilation),
represents an independent predictor for major bleeding
according to both classifications. Besides, ultrafiltration and
IABP require heparin.
It is interesting to note that GPI administration was not
associated with an increased incidence of bleeding. On the
other hand, ACUITY,6,21–22 in agreement with the Global
Registry of Acute Coronary Events (GRACE) registry,23
reported that GPI, among other factors, independently
predicted major bleeding. Discrepancies between our study
and previous ones can be related to the fact that our
investigation is not a randomized one and it can be
speculated thatGPI usewas administered by cardiologists to
patients believed to be at lower risk for bleeding. Similarly,
the higher use of bare-metal stents observed in patients who
experiencedmajor bleeding according to TIMI classification
can be related to cardiologists’ decisions to use them in
patients believed to be at higher risk for bleeding.
In our series, in regard to bleeding sites, in both
classifications about half of the clinical bleeding events
were related to femoral groin hematoma. The transradial
approach is supposed to substantially reduce the rate of this
complication.24
A possible limitation of the study is that it is retrospective.
However, it included a large series of STEMI patients all
subjected to primary PCI with no age or gender restriction,
thus mirroring the real-world scenario.
Conclusion
In STEMI patients who undergo primary PCI and receive
dual antiplatelet therapy, TIMI is more capable than
ACUITY in identifying patients with major bleeding at
higher risk for early mortality. The presence of renal failure
represents an independent predictor for major bleeding.
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